- This topic has 3 replies, 3 voices, and was last updated 1 week, 2 days ago by
.
-
Posts
-
I was reading about weight management compounds and I see both AOD-9604 and Fragment 176-191 listed. From what I can tell they’re both derived from the same region of the HGH molecule. Are they actually different compounds or is one just a branded version of the other?
Also, I keep seeing conflicting information about whether AOD-9604 reached phase 3 trials. What’s the actual history there?
Great question and the confusion is understandable, they’re closely related but not identical.
Fragment 176-191 refers specifically to amino acids 176-191 of the hGH sequence. AOD-9604 is a modified version of that same fragment with an added tyrosine residue at the N-terminus, which was designed to improve stability and activity.
So: Fragment 176-191 is the naturally-occurring sequence; AOD-9604 is a synthetic modification of it. In practice many people use the names interchangeably which adds to the confusion.
On the clinical history: AOD-9604 did advance through clinical trials (including Phase 2b for obesity) and received FDA GRAS (Generally Recognized As Safe) status as a food ingredient. It didn’t complete Phase 3 for the obesity indication, but the GRAS designation is notable and distinguishes it from many research peptides.
Alex nailed it. The GRAS designation is worth paying attention to, it’s a meaningful distinction in terms of safety research compared to many other compounds in this space.
From a research standpoint the mechanisms are similar (both appear to act on the fat-specific receptor rather than general GH receptors, which is why neither produces the insulin resistance concerns associated with full hGH). The modification in AOD-9604 theoretically improves bioavailability but comparing them head-to-head in human studies is difficult since most data is in animal models.
- You must be logged in to reply to this topic.
